MYLAN-MOXIFLOXACIN 400 MG — DIN 02406136
MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) : 400 MG · MYLAN PHARMACEUTICALS ULC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED PRE MARKET
What is MYLAN-MOXIFLOXACIN?
MYLAN-MOXIFLOXACIN 400 MG contains MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) : 400 MG. It is listed in the Health Canada Drug Product Database under DIN 02406136, held by MYLAN PHARMACEUTICALS ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled pre market, status dated 11-Jan-2017. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is MYLAN-MOXIFLOXACIN used for?
Acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, and community acquired pneumonia (mild to moderate) in adults (>=18 years).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Moxifloxacin cost around the world?
Moxifloxacin is listed on 12 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| South Africa | single exit price | 20 | 27 | ZAR███.██ |
| United States | acquisition | 2 | 21 | USD███.██ |
| Bahrain | retail (max) | 11 | 17 | BHD███.██ |
| Austria | KVP (Kassenverkaufspreis) | 6 | 15 | EUR███.██ |
| Sweden | AIP (pharmacy purchase price) | 6 | 14 | SEK███.██ |
| Greece | producer price (ex-factory) | 13 | 13 | EUR███.██ |
| Romania | max producer price | 9 | 13 | RON███.██ |
| Luxembourg | reimbursement | 8 | 8 | EUR███.██ |
| Hungary | producer price (ex-factory) | 2 | 7 | HUF███.██ |
| Iceland | max wholesale | 3 | 3 | ISK███.██ |
| United Kingdom | hospital | 2 | 2 | GBP███.██ |
| Czechia | max producer price (ex-factory) | 1 | 1 | CZK███.██ |
141 pack listings across 83 brand entries and 11 price bases, refreshed 05 Sep 2026. Ranges span every Moxifloxacin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Moxifloxacin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
21 holders have a Canadian DIN containing Moxifloxacin, across 25 DINs, of which 8 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| JAMP PHARMA CORPORATION | 2 | 1 | JAMP-MOXIFLOXACIN, JAMP-MOXIFLOXACIN TABLETS | Sourceable in Canada |
| AURO PHARMA INC | 1 | 1 | AURO-MOXIFLOXACIN | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 1 | 1 | MOXIFLOXACIN INJECTION | Sourceable in Canada |
| MANTRA PHARMA INC | 1 | 1 | M-MOXIFLOXACIN | Sourceable in Canada |
| PRO DOC LIMITEE | 1 | 1 | MOXIFLOXACIN | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 1 | 1 | SANDOZ MOXIFLOXACIN | Sourceable in Canada |
| SANIS HEALTH INC | 1 | 1 | MOXIFLOXACIN | Sourceable in Canada |
| TEVA CANADA LIMITED | 1 | 1 | TEVA-MOXIFLOXACIN | Sourceable in Canada |
| APOTEX INC | 2 | 0 | APO-MOXIFLOXACIN, APO-MOXIFLOXACIN HYDROCHLORIDE | No marketed DIN |
| BAYER INC | 2 | 0 | AVELOX, AVELOX I.V. | No marketed DIN |
| MARCAN PHARMACEUTICALS INC | 2 | 0 | IPG-MOXIFLOXACIN, MAR-MOXIFLOXACIN | No marketed DIN |
| TORRENT PHARMACEUTICALS LIMITED | 1 | 0 | TORRENT-MOXIFLOXACIN | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 400 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in provided text (mentions 'component of the container'). |
| Storage | Not explicitly detailed in provided text (refer to 'STORAGE AND STABILITY' section 29). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Moxifloxacin |
|---|---|
| ATC code | J01MA14 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02406136 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2406136 |
| Brand name | MYLAN-MOXIFLOXACIN |
| Generic / active ingredient | MOXIFLOXACIN (MOXIFLOXACIN HYDROCHLORIDE) : 400 MG |
| Market authorization holder | MYLAN PHARMACEUTICALS ULC |
| Health Canada schedule | Prescription |
| ATC code | J01MA14 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01MA |
| Current status | CANCELLED PRE MARKET |
| Status date | 11-Jan-2017 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
400 mg once daily. Recommended duration of infusion for IV is 60 minutes; do not exceed recommended dose.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to moxifloxacin, other quinolones, or any ingredient in the formulation.
Warnings and precautions
QT interval prolongation; serious hypersensitivity/anaphylaxis; increased risk of tendinitis/tendon rupture; exacerbation of myasthenia gravis; seizures; fulminant hepatitis.
Is Moxifloxacin in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
8 of 25 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-MOXIFLOXACIN | 400 MG | TABLET | AURO PHARMA INC | MARKETED | 02432242 |
| JAMP-MOXIFLOXACIN | 400 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02443929 |
| M-MOXIFLOXACIN | 400 MG | TABLET | MANTRA PHARMA INC | MARKETED | 02472791 |
| MOXIFLOXACIN | 400 MG | TABLET | PRO DOC LIMITEE | MARKETED | 02462974 |
| MOXIFLOXACIN | 400 MG | TABLET | SANIS HEALTH INC | MARKETED | 02520710 |
| MOXIFLOXACIN INJECTION | 400 MG / 250 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02433087 |
| SANDOZ MOXIFLOXACIN | 400 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | 02383381 |
| TEVA-MOXIFLOXACIN | 400 MG | TABLET | TEVA CANADA LIMITED | MARKETED | 02375702 |
| AG-MOXIFLOXACIN | 400 MG | TABLET | ANGITA PHARMA INC. | DORMANT | 02478137 |
| APO-MOXIFLOXACIN | 400 MG | TABLET | APOTEX INC | DORMANT | 02404923 |
2 · Same class — other molecules in ATC J01MA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Ciprofloxacin | ACT CIPROFLOXACIN · AG-CIPROFLOXACIN · APO-CIPROFLOX · AURO-CIPROFLOXACIN · BIO-CIPROFLOXACIN · CIPRO · CIPRO 100 - TAB 100MG · CIPRO I.V. - LIQ 10MG/ML · CIPRO I.V. MINIBAGS 2MG/ML · CIPRO IV 10MG/ML · CIPRO ORAL SUSPENSION · CIPRO TAB 100MG · CIPRO TAB 250MG · CIPRO TAB 500MG · CIPRO TAB 750MG · CIPRO XL · CIPROFLOXACIN · CIPROFLOXACIN INJECTION · CIPROFLOXACIN INJECTION USP · CIPROFLOXACIN INJECTION, USP · CIPROFLOXACIN INTRAVENOUS INFUSION · CIPROFLOXACIN INTRAVENOUS INFUSION BP · CIPROFLOXACIN INTRAVENOUS INFUSION, BP · CIPROFLOXACIN OMEGA · CIPROFLOXACIN TABLETS · CIPROFLOXACIN TABLETS USP · CIPROFLOXACIN-250 · CIPROFLOXACIN-500 · CIPROFLOXACIN-750 · DOM-CIPROFLOXACIN · IPG-CIPROFLOXACIN · JAMP-CIPROFLOXACIN · MAR-CIPROFLOXACIN · MINT-CIPROFLOX · MINT-CIPROFLOXACIN · MYLAN-CIPROFLOXACIN · MYLAN-CIPROFLOXACIN XL · NRA-CIPROFLOXACIN · NU-CIPROFLOXACIN TABLETS · PHL-CIPROFLOXACIN · PMS-CIPROFLOXACIN · PMS-CIPROFLOXACIN XL · PRIVA-CIPROFLOXACIN · PRO-CIPROFLOXACIN · Q-CIPROFLOXACIN · RAN-CIPROFLOXACIN · RATIO-CIPROFLOXACIN · RIVA-CIPROFLOXACIN · SANDOZ CIPROFLOXACIN · SEPTA-CIPROFLOXACIN · TARO-CIPROFLOX · TARO-CIPROFLOXACIN · TEVA-CIPROFLOXACIN · VAN-CIPROFLOXACIN | 139 | 29 | Yes |
| Levofloxacin | ACT LEVOFLOXACIN · APO-LEVOFLOXACIN · AURO-LEVOFLOXACIN · AVA-LEVOFLOXACIN · DOM-LEVOFLOXACIN · JAMP LEVOFLOXACIN · LEVAQUIN · LEVAQUIN 25MG/ML · LEVAQUIN 500MG · LEVAQUIN 5MG/ML · LEVAQUIN 750MG · LEVOFLOXACIN · LEVOFLOXACIN IN 5% DEXTROSE INJECTION · LEVOFLOXACIN INJECTION · MINT-LEVOFLOXACIN · MYLAN-LEVOFLOXACIN · NTP-LEVOFLOXACIN · PHL-LEVOFLOXACIN · PMS-LEVOFLOXACIN · QUINSAIR · RIVA-LEVOFLOXACIN · SANDOZ LEVOFLOXACIN · TEVA-LEVOFLOXACIN | 54 | 16 | Yes |
| Moxifloxacin | AG-MOXIFLOXACIN · APO-MOXIFLOXACIN · APO-MOXIFLOXACIN HYDROCHLORIDE · AURO-MOXIFLOXACIN · AVELOX · AVELOX I.V. · BIO-MOXIFLOXACIN · DOM-MOXIFLOXACIN · IPG-MOXIFLOXACIN · JAMP-MOXIFLOXACIN · JAMP-MOXIFLOXACIN TABLETS · M-MOXIFLOXACIN · MAR-MOXIFLOXACIN · MED-MOXIFLOXACIN · MOXIFLOXACIN · MOXIFLOXACIN INJECTION · MYLAN-MOXIFLOXACIN · PHL-MOXIFLOXACIN · PMS-MOXIFLOXACIN · PRIVA-MOXIFLOXACIN · RIVA-MOXIFLOXACIN · SANDOZ MOXIFLOXACIN · TEVA-MOXIFLOXACIN · TORRENT-MOXIFLOXACIN | 25 | 8 | Yes |
| Delafloxacin | BAXDELA | 2 | 2 | Yes |
| Norfloxacin | AVA-NORFLOXACIN · CO NORFLOXACIN · NORFLOXACIN · NORFLOXACINE-400 · NOROXIN · NTP-NORFLOXACIN · PMS-NORFLOXACIN · RIVA-NORFLOXACIN · TEVA-NORFLOXACIN | 12 | 1 | Yes |
| Ofloxacin | FLOXIN I.V. LIQ 20MG/ML · FLOXIN TABLETS 200MG · FLOXIN TABLETS 300MG · FLOXIN TABLETS 400MG · NOVO-OFLOXACIN · OFLOXACIN TABLETS | 10 | 0 | Not in Canada |
| Gatifloxacin | NOVO-GATIFLOXACIN · TEQUIN · TEQUIN IV | 5 | 0 | Not in Canada |
| Trovafloxacin | TROVAN I.V. · TROVAN TABLETS 100MG · TROVAN TABLETS 200MG | 3 | 0 | Not in Canada |
| Grepafloxacin | RAXAR | 1 | 0 | Not in Canada |
| Gemifloxacin | FACTIVE | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01M
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01MB | Nalidixic Acid | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is MYLAN-MOXIFLOXACIN called?
The same molecule, Moxifloxacin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Avalox | Latin | Bahrain, Iceland |
| Avelox | Latin | Iceland, Sweden |
| Moxifloxacin Krka | Latin | Sweden |
| Moxifloxacin Orion | Latin | Sweden |
| Avoxa | Latin | South Africa |
| DRL Moxifloxacin | Latin | South Africa |
| Litares | Latin | South Africa |
| MICROMOX | Latin | Bahrain |
| Moxibay Tablets | Latin | South Africa |
| Moxifloxacin Abacus Medicine | Latin | Sweden |
| MOXIVE | Latin | Bahrain |
| MUXAVA | Latin | Bahrain |
| Ran-Moxifloxacin | Latin | South Africa |
| XFLOX | Latin | Bahrain |
| AROX | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.